“friends and foes” of multiple myeloma measurable/minimal residual disease evaluation by next generation flow

HIGHLIGHTS

• who: Paola Pacelli from the Cornell University, United States have published the article: u201cFriends and foesu201d of multiple myeloma measurable/minimal residual disease evaluation by next generation flow, in the Journal: (JOURNAL)

SUMMARY

Multiple Myeloma (MM) is a Plasma Cells (PCs) malignancy characterized by the uncontrolled proliferation of pathologic PCs in the Bone Marrow (BM). Strategies such as consolidation therapy and maintenance after Autologous Stem Cell Transplantation (ASCT) contribute to further improvement of PFS and OS. Timing of MRD testing is also important and should be at treatment cessation 3 months after autologous . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or E-mail:

If you don't have an account, you can create one here.